1200129-48-1

1200129-48-1 structure

Name: GDC-0425
Chemical Name: 5-[(1-Ethyl-4-piperidinyl)oxy]-9H-pyrido[4',3':4,5]pyrrolo[2,3-b]pyridine-6-carbonitrile
CAS Number: 1200129-48-1
Molecular Formula: C₁₈H₁₉N₅O
Molecular Weight: 321.38
Catalog: Signaling Pathways Cell Cycle/DNA Damage Checkpoint Kinase (Chk)
Create Date: 2018-06-12 10:17:40
Modify Date: 2025-08-25 17:26:39
GDC-0425 (RG-7602) is an orally available, highly selective small molecule ChK1 inhibitor. GDC-0425 can be used for the research of various malignancies[1][2].

Name	5-[(1-Ethyl-4-piperidinyl)oxy]-9H-pyrido[4',3':4,5]pyrrolo[2,3-b]pyridine-6-carbonitrile
Synonyms	5-[(1-Ethyl-4-piperidinyl)oxy]-9H-pyrido[4',3':4,5]pyrrolo[2,3-b]pyridine-6-carbonitrile 9H-Pyrrolo[2,3-b:5,4-c']dipyridine-6-carbonitrile, 5-[(1-ethyl-4-piperidinyl)oxy]-

Description	GDC-0425 (RG-7602) is an orally available, highly selective small molecule ChK1 inhibitor. GDC-0425 can be used for the research of various malignancies[1][2].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Cell Cycle/DNA Damage >> Checkpoint Kinase (Chk)
Target	Chk1
In Vitro	MEK inhibition either by pharmacologic inhibitors or RNAi-mediated gene silencing significantly protected cells from reduced viability upon GDC-0425 treatment[3]. GDC-0425 (3 μM; 24 hours) treatment results the hyperphosphorylation of Chk1[3]. Cell Viability Assay[3] Cell Line: Chk1-positive breast cancer cell lines Concentration: 0.001, 0.01, 0.1, 1, 10 mM Incubation Time: 72 hours Result: Reduced cell proliferation. Cell Viability Assay[3] Cell Line: U-2 OS cells Concentration: 3 μM Incubation Time: 24 hours Result: Led to hyperphosphorylation of Chk1.
In Vivo	GDC-0425 exhibits partial suppression of tumor growth. The Gemcitabine/GDC-0425 combination results in significant tumor regression in all tested models[3]. Animal Model: NCr nude mice bearing xenografts of both osteosarcoma and triple-negative breast cancer models (143B PML BK TK, HCC1806, and HCC70 cell lines)[3] Dosage: For the 4-arm study, mice were treated with vehicle, Gemcitabine 120 mg/kg, GDC-0425 75 mg/kg alone, or Gemcitabine and GDC-0425 combination for 15 days. For 6-arm studies of HCC1806 and HCC70 models, mice were treated with vehicle, Gemcitabine 120 mg/kg, GDC-0425 50 mg/kg, GDC-0425 75 mg/kg alone, or Gemcitabine and GDC-0425 combination. Administration: Orally administrated at 24, 48, and 72 hours after gemcitabine administration by intraperitoneal injection. Result: Exhibited partial suppression of tumor growth upon treatment with either Gemcitabine or GDC-0425 alone. Notably, the Gemcitabine/GDC-0425 combination resulted in significant tumor regression in all tested models.
References	[1]. Xiao Ding, et al. A supported liquid extraction LC-MS/MS method for determination of concentrations of GDC-0425, a small molecule Checkpoint kinase 1 inhibitor, in human plasma. Biomed Chromatogr. 2016 Dec;30(12):1984-1991. [2]. Jeffrey R Infante, et al. Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors. Clin Cancer Res. 2017 May 15;23(10):2423-2432. [3]. Ho-June Lee, et al. Ras-MEK Signaling Mediates a Critical Chk1-Dependent DNA Damage Response in Cancer Cells. Mol Cancer Ther. 2017 Apr;16(4):694-704.

Density	1.3±0.1 g/cm3
Boiling Point	589.2±50.0 °C at 760 mmHg
Molecular Formula	C₁₈H₁₉N₅O
Molecular Weight	321.38
Flash Point	310.2±30.1 °C
Exact Mass	321.158966
LogP	3.82
Vapour Pressure	0.0±1.7 mmHg at 25°C
Index of Refraction	1.686

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.

1200129-48-1	1434048-34-6
2238822-07-4	1637394-01-4
1001264-89-6	2252277-73-7
1382979-44-3	2377352-49-1
957054-30-7	1133432-50-4
1081123-92-3	1081123-94-5
1081123-96-7	1081123-98-9
1081123-99-0	1081124-02-8
1049126-09-1	1081124-09-5
1040713-27-6	1081124-24-4